Asset Details
Do you wish to reserve the book?
Imaging the neuroplastic effects of ketamine with VBM and the necessity of placebo control
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Imaging the neuroplastic effects of ketamine with VBM and the necessity of placebo control
Do you wish to request the book?
Imaging the neuroplastic effects of ketamine with VBM and the necessity of placebo control
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Imaging the neuroplastic effects of ketamine with VBM and the necessity of placebo control
2017
Overview
In the last years a plethora of studies have investigated morphological changes induced by behavioural or pharmacological interventions using structural T1-weighted MRI and voxel-based morphometry (VBM). Ketamine is thought to exert its antidepressant action by restoring neuroplasticity. In order to test for acute impact of a single ketamine infusion on grey matter volume we performed a placebo-controlled, double-blind investigation in healthy volunteers using VBM. 28 healthy individuals underwent two MRI sessions within a timeframe of 2 weeks, each consisting of two structural T1-weighted MRIs within a single session, one before and one 45min after infusion of S-ketamine (bolus of 0.11mg/kg, followed by an maintenance infusion of 0.12mg/kg) or placebo (0.9% NaCl infusion) using a crossover design. In the repeated-measures ANOVA with time (post-infusion/pre-infusion) and medication (placebo/ketamine) as factors, no significant effect of interaction and no effect of medication was found (FWE-corrected). Importantly, further post-hoc t-tests revealed a strong “decrease” of grey matter both in the placebo and the ketamine condition over time. This effect was evident mainly in frontal and temporal regions bilaterally with t-values ranging from 4.95 to 5.31 (FWE-corrected at p<0.05 voxel level). The vulnerabilities of VBM have been repeatedly demonstrated, with reports of influence of blood flow, tissue water and direct effects of pharmacological compounds on the MRI signal. Here again, we highlight that the relationship between intervention and VBM results is apparently subject to a number of physiological influences, which are partly unknown. Future studies focusing on the effects of ketamine on grey matter should try to integrate known influential factors such as blood flow into analysis. Furthermore, the results of this study highlight the importance of a carefully performed placebo condition in pharmacological fMRI studies.
•The study aimed to evaluate the effects of ketamine on brain structure using VBM.•No effects of ketamine using a double-blind, placebo-controlled, cross-over design.•Drug-unspecific strong “decrease” of grey matter over time.•VBM results are influenced by a parameters independent of “real” changes of brain structure.•Study highlights the importance of placebo condition in pharmacological MRI studies.
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Anesthetics, Dissociative - pharmacology
/ Brain
/ Cerebrovascular Circulation - physiology
/ Female
/ Functional magnetic resonance imaging
/ Gray Matter - anatomy & histology
/ Humans
/ Image Processing, Computer-Assisted - methods
/ Ketamine
/ Male
/ MRI
/ Neuronal Plasticity - drug effects
/ Placebos
/ Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors
/ Rodents
/ Studies
/ VBM
